The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2018 | Novel ventoclax combinations for CLL
The future of chronic lymphocytic leukemia (CLL) treatment is bright and looking towards novel combinations. Here, Eva Kimby, MD, PhD, of the Karolinska University Hospital, Solna, Sweden, gives us her thoughts on promising novel therapies, including venetoclax combinations. This interview took place at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
